Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JDQ433
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JDQ433 is an investigational small molecule inhibitor targeting the KRAS G12C mutation, a common oncogenic driver in various solid tumors. Developed by Novartis, it is primarily studied for the treatment of KRAS G12C-mutated non-small cell lung cancer (NSCLC) and other solid tumors. The compound is frequently mentioned in the context of the KontRASt-01 phase 1b/2 trial (NCT04699188), where it is evaluated as a monotherapy and in combination with the SHP2 inhibitor TNO155. Note that official trial documentation and the Novartis pipeline identify the clinical candidate as JDQ443 (opnurasib), indicating that JDQ433 is likely a misnomer for JDQ443.
02
Targets
KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)
Beyond the preview
Go deeper on JDQ433.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JDQ433.